India, Nov. 2 -- Edwards Lifesciences (EW) reported Phase 3 PROGRESS trial results showing that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in patients with moderate aortic stenosis who had features associated with a higher risk of disease progression.
Aortic stenosis (AS) is a condition in which the heart's aortic valve narrows, restricting blood flow from the heart to the rest of the body. Patients with moderate disease have traditionally been monitored through regular checkups and imaging tests rather than receiving early intervention.
In the PROGRESS trial, TAVR reduced the risk of the combined endpoint of death or heart failure events by 33% over two years compared with clinical surveillance. E...